Product
BIKTARVY
Aliases
BIKTARVY 50Mg-200Mg-25Mg Tablet
3 clinical trials
3 indications
Indication
HIV InfectionsIndication
HIVIndication
HIV-1 infectionClinical trial
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically SuppressedStatus: Completed, Estimated PCD: 2022-07-13
Clinical trial
Efficacy, Tolerability and Acceptability of the Single Table Regimen (STR) Biktarvy® by Trans People Living With HIV (TPLWH)Status: Terminated, Estimated PCD: 2023-05-11
Clinical trial
The Effect of Biktarvy (B/F/TAF) on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy VolunteersStatus: Recruiting, Estimated PCD: 2023-10-30